Results 301 to 310 of about 840,133 (341)

Correction for Jang et al., Lipid raft proteomics identify endothelial myosin-9 (MYH9) as a regulator of low-density lipoprotein transcytosis and atherosclerosis. [PDF]

Proc Natl Acad Sci U S A
europepmc   +1 more source

Serum proteins associated with LDL-C and non-HDL-C reduction in response to dietary interventions in the DASH and DASH-Sodium trials.

Food Funct
Kim H, Lichtenstein AH, Coresh J, Appel LJ, Rebholz CM.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Lipoprotein Apheresis

Endocrinology and Metabolism Clinics of North America, 2015
Patients with familial hypercholesterolemia (FH) have early development of atherosclerosis and cardiovascular disease (CVD). Lipid level-lowering medications are not always successful in reducing increased low-density lipoprotein C (LDL-C) levels. Lipoprotein apheresis (LA) therapy has proven its clinical benefit in reducing CVD events for patients ...
Patrick M, Moriarty, Linda, Hemphill
openaire   +3 more sources

Lipoprotein(a) and ethnicities

Atherosclerosis, 2022
The initial studies focusing on lipoprotein(a) [Lp(a)] and its role in atherosclerotic cardiovascular disease were conducted exclusively in Whites. Subsequently, multiple large-scale, independent investigations have established clear race/ethnic differences in plasma Lp(a) concentration and population distribution over the last four decades.
Anurag, Mehta, Vardhmaan, Jain, Anum, Saeed, Joseph J, Saseen, Martha, Gulati, Christie M, Ballantyne, Salim S, Virani   +6 more
openaire   +2 more sources

The Biochemistry of Lipoproteins

Journal of Inherited Metabolic Disease, 1988
SummaryLipids are transported in the blood in four major classes of lipoproteins. The triacylglycerol‐rich lipoproteins are chylomicrons and very‐low‐density lipoproteins (VLDL) which are produced by the small intestine and liver, respectively. These lipoproteins mainly carry fatty acids to adipose tissue and muscle where the triacylglycerol is ...
A M, Salter, D N, Brindley
openaire   +2 more sources

Lipoprotein apheresis for lipoprotein(a) and cardiovascular disease

Journal of Clinical Lipidology, 2019
Elevated lipoprotein(a) [Lp(a)] is an independent risk factor for cardiovascular disease (CVD). In the United States, lipoprotein apheresis (LA) therapy is approved for patients with familial hypercholesterolemia. Germany uses LA therapy for patients with an Lp(a) > 60 mg/dL, normal low-density lipoprotein cholesterol (LDL-C) levels, and CVD.
Patrick M, Moriarty, Jessica V, Gray, Lauryn K, Gorby   +2 more
openaire   +2 more sources

Lipoprotein (a)

Baillière's Clinical Endocrinology and Metabolism, 1995
Lipoprotein (a) is similar to low-density lipoprotein but is unique in having an additional apolipoprotein called apolipoprotein (a) (apo(a)) covalently linked to it. apo(a), which is a member of the plasminogen gene superfamily, has a protease domain which cannot be activated to cause fibrinolysis.
openaire   +2 more sources